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Protein Sequencing with an Adaptive Genetic Algorithm from
Tandem Mass Spectrometry
Jean-Charles Boisson, Laetitia Jourdan, El-Ghazali Talbi and Christian Rolando
Abstract— In Proteomics, only the de novo peptide sequencing
approach allows a partial amino acid sequence of a peptide to
be found from a MS/MS spectrum. In this article a preliminary
work is presented to discover a complete protein sequence from
spectral data (MS and MS/MS spectra). For the moment, our
approach only uses MS spectra. A Genetic Algorithm (GA)
has been designed with a new evaluation function which works
directly with a complete MS spectrum as input and not with
a mass list like the other methods using this kind of data.
Thus the mono isotopic peak extraction step which needs a
human intervention is deleted. The goal of this approach is
to discover the sequence of unknown proteins and to allow a
better understanding of the differences between experimental
proteins and proteins from databases.
I. INTRODUCTION
Proteomics is a recent research domain which has emerged
thanks to the mass spectrometry 10-15 years ago. It can be
defined as the global analysis of proteins. The word proteome
defines the protein set of an organism. Figure 1 represents a
global scheme starting from the genes to the proteins.
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Fig. 1
GLOBAL SCHEME: FROM GENOME TO PROTEOME (HUMAN CASE).
The Proteomics main goal is the experimental protein
identification. Several general techniques exist and a lot of
identification tools can be used to make experimental protein
identification (the well known Mascot [1] for example). MS
spectra is the most common data used to make a first step
of identification. It is a mass/intensity spectrum where each
peak generally corresponds to a peptide of the experimental
protein. A peptide is a subset of the original protein obtained
by a digestion mechanism. In this digestion a protein is cut at
specific cleavage points by an enzyme. From a MS spectrum,
a mono isotopic mass list is extracted and used for the
identification process. In order to make this identification, the
Peptide Mass Fingerprinting (PMF) techniques take proteins
from databases and theoretically digest them in order to
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suit with the experimental data. These methods compare
the experimental mass list with theoretical mass lists and
allow to find the protein which has the best score [2], [3].
The accuracy of these methods can be increased thanks to
tandem mass spectrometry. The tandem mass spectrometry
corresponds to using MS/MS spectra in addition of MS
spectra. A MS/MS spectrum is also a mass/intensity spectrum
but each peak generally corresponds to one ion type. In fact,
a MS/MS (or MS2) is the result of the fragmentation of
one peptide. So for each peptide, a MS/MS spectrum is
generated. These spectra give more information to identify
close proteins than MS spectra [4], [5].
An another way to use MS/MS spectra is to make iden-
tification by de novo sequencing. Theoretically, if the ions
resulting of a peptide fragmentation can be all kept in the
right order, the peptide sequence can be found. However, the
MS/MS spectra are noisy and only small sequences can be
deduced. So the de novo sequencing methods manage to find
the right peptide sequence to help the protein identification.
These methods start from random peptide sequences or from
sequences gained by another identification tool in order to
find the right peptide sequence thanks to MS/MS spectra [6],
[7], [8], [9]. The main problem of this approach is the
huge research space of potential peptide sequences. Some
optimization methods have been used with good results [10],
[8]. Furthermore, the complete identification process need to
be assisted by a sequence alignment tool like Blast to be
complete.
A complete automatizing of all the de novo peptide se-
quencing process is interesting. But if a complete automatic
de novo sequencing approach can be used on all the peptides
of one protein, a protein can be sequenced. Inspired by this
idea, we propose a complete approach for making protein
sequencing.
Figure 2 illustrates this approach. From a MS spectrum
(peptide level) and MS/MS spectra (ion level), the closest
protein sequence may be generated. The originality of this
work is that whereas all the other approaches use a list of
peptide masses manually extracted thanks to a proprietary
software from the spectrometer seller, we directly use a MS
spectrum issued of the spectrometer. Furthermore discov-
ering protein sequences is the only way to identify pro-
teins unknown from databases. An other interest of protein
sequencing is the possibility to detect sequence variations
between the experimental protein and its representation in the
databases. In this article, the first step of our approach that
allows to find the experimental peptide chemical formula is
presented. In section II each part of the chosen optimization
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Fig. 2
GENERAL APPROACH SCHEME. “MS”(“MS/MS”) EVALUATION:
INDIVIDUAL EVALUATION WITH A MS (MS/MS) SPECTRUM.
method, a Genetic Algorithm (GA), is exposed. In section III,
the statistics concerning the GA behavior and the first results
of our approach is presented. Finally, section IV deals with
the conclusions and perspectives about this work.
II. A SPECIFIC GENETIC ALGORITHM
In this section the global scheme of our approach is
presented with an explanation of the digestion process. Then
each GA part is carefully described. Figure 3 represents
the actual version of our approach in which only the MS
evaluation is proposed.
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ACTUAL APPROACH SCHEME. “MS” EVALUATION: INDIVIDUAL
EVALUATION WITH A MS SPECTRUM.
A. The approach
In this part, the global approach and the theoretical
digestion process are presented.
1) Description: a protein can be described as a sorted
set of peptides. On the one hand a MS spectrum can
help to globally identify the peptides which composed
the experimental protein without any information on
their sequences or their order. On the other hand a
MS/MS spectrum which corresponds to a peptide can give
information about the peptide sequence. So from MS and
MS/MS spectra, the peptide sequences may be available but
the peptides may not be necessary in the right order. For the
moment, a genetic algorithm has been designed with an new
evaluation function working on a MS spectrum in order to
find the chemical formulae of the peptides that compounds
the experimental protein. Our evaluation function directly
compares an experimental spectrum with a simulated
spectrum generated from an amino acid sequence. This
evaluation function may allow to find the right chemical
formula (and so the right mass) of the peptides. In order
to generate a simulated spectrum which can be compared
with a MS spectrum, the analyzed protein has to be in a
peptide list format. To do that, a theoretical digestion has
to be executed. The next paragraph describes the digestion
algorithm that we have designed.
2) The Digestion Process: in order to be analyzed, ex-
perimental proteins are cut by an enzyme before being put
in the mass spectrometer: it is the digestion step. There are
several kind of enzyme and each of them cuts proteins on
specific cleavage point. In fact, each enzyme respects its
own cleavage grammar. For example, the trypsin enzyme
cuts proteins after the amino acids lysine (K) and arginine
(R) if they are not followed by a proline (P). However, in
the real digestion process, enzyme can miss cleavage points
and so the result peptides can have “miss cleavage”. Due
to these miss cleavages, the number of potential peptides
that can be generated by the digestion process is increased.
The developed theoretical digestion algorithm is an linear
and iterative algorithm with no limitations in the number of
considered miss cleavages.
B. the GA
In our approach, we want to sequence proteins. The search
space linked to this goal can be described as follow: accord-
ing to the size of a protein in amino acids (n) and the number
of existing amino acids (20), there are 20n potential proteins
that can be generated. Nevertheless n is unknown. Generally
it is in [100, 10000] amino acids. However, bounds can be
computed in order to reduce this range according to the ex-
perimental protein mass (see “population initialization” part).
If we add static and variable post translational modifications,
the number of potential proteins (already huge) explodes.
So we need an optimization method that can work on very
huge search space. That is why a genetic algorithm has
been chosen. The initial protein population evolves according
to specific crossover and mutation operators [11]. Figure 4
shows the global scheme of a GA.
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THE GENERAL FLOWCHART OF A GENETIC ALGORITHM. p IS THE
PROBABILITY OF MUTATION.
Each part of the GA has been designed for our problem.
1) Encoding: For an individual, there are three possible
manner to encode it. An individual could be:
• An amino acid chain: it is the simplest representation.
At each evaluation, the individual need to be digested
(MS evaluation) and fragmented (MS/MS evaluation).
• A peptide list: an individual is digested one time at its
initialization, only miss cleavage computation need to
be updated when an operator modifies an individual.
From the peptide list, it is easy to return to the original
amino acid chain. However, to be evaluated with a
MS/MS evaluation function, the peptide list needs to
be fragmented.
• A ions list: a MS/MS evaluation is direct but returning
to peptide level or protein level is very difficult.
Finally, the second representation has been chosen because
it is easy to return to protein level and MS evaluation is
direct. An individual is a list of peptides (with the number
of miss cleavage), each peptide is an amino acid chain and
each amino acid can have post-translational modifications.
2) Population initialization: population is randomly
initialized with a variable size (in amino acids). This size is
contained between two bounds which are calculated from
the estimated experimental protein mass. From this mass, we
compute a minimum protein mass and a maximum protein
mass (experimental mass ±10 percents). The upper (lower)
bound is calculated thanks to the maximum (minimum)
protein mass and the amino acid that has the smallest
(biggest) mass. So a maximum range for the protein size (in
amino acid) is obtained. Nevertheless the generated protein
mass has to be checked in order to be validated.
3) Fitness function: the evaluation function compares an
individual, transformed into a theoretical MS spectrum, with
an experimental MS spectrum. A major interest of this
function is to compare a MS spectrum with a simulated one
(peptide by peptide). The evaluation function does not need
a mono isotopic mass list extracted from the experimental
MS spectrum. In order to generate a simulated spectra, we
design a spectrum generator based on a algorithm developed
by A.L. Rockwood [12] to compute isotopic distribution. For
detail our fitness function, we use the following notations: n
is the protein size in amino acids, m is the protein number
of peptides, na is the number of elements in a chemical
formula, nxq is the quantity of element X in a chemical
formula and N is the array size that contains a spectrum. N
is a very important parameter as its value sets the number of
points that describes the spectrum. The higher N is, the more
accurate is the spectrum. The used Fast Fourier Transform
(FFT) algorithm is in Nlog2N . Figure 5 details the 4 steps
to evaluate an individual.
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EVALUATION OF AN INDIVIDUAL.
We begin from an individual i.e. from a peptide list:
1) The peptide list is transformed into a chemical formula
list. This step is linear in the protein size: O(n).
2) Each chemical formula allows to generate a part of
the complete simulated spectrum. To do that, the
isotopic distribution of each formula is computed.
For an element X, its initial isotopic distribution is
computed (X1 in O(N)). Then FFT allows to change
to the Fourier space (O(Nlog2N)). In order to find
the isotopic distribution for Xq , nxq multiplications
are needed (O(nxq ∗ N)). The isotopic distributions
of each element has to be added together (O(na ∗N)).
Finally, FFT allows to return to the Euclidian space
(O(Nlog2N)). So this step is in:
O(N + 2Nlog2N + na ∗ nxq ∗N + na ∗N)
⇔ O(N ∗ (1 + 2log2N + na(nxq + 1)))
≈ O(Nlog2N), 1≪ na ∗ nxq ≪ N
By default, N has a value of 65536(216).
3) Each part of the simulated spectrum (so each pep-
tide spectrum) is compared with the experimental MS
spectrum. A partial score associated to a peptide is
calculated. The peptides are classified according to
their score:
• Positive score: good correlation. The peptide
appears in the two spectra and the isotopic
distribution is very similar (Figure 6, case A).
• Negative score: bad correlation. There is maybe a
peptide in the experimental spectrum but it is not
similar to the theoretical peptide (Figure 6, case
B).
• The lowest scoring bound: no correlation. There
is nothing in the experimental spectrum (Figure 6,
case C). The lowest scoring bound is dynamically
computed according the evaluation function
configuration.
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Fig. 6
CORRELATION BETWEEN A THEORETICAL PEPTIDE AND THE
EXPERIMENTAL SPECTRUM. CASE A: GOOD CORRELATION, CASE B: BAD
CORRELATION AND CASE C: NO CORRELATION. M/Z = MASS / CHARGE.
This step is linear in the spectrum point number
(O(N)).
4) The complete theoretical spectrum is finished. Using
the peptide partial scores and the global similarity
between the two spectra give the individual fitness.
This final step is also linear in the spectrum point
number(O(N)).
The original global complexity of our evaluation function
is:
O(n+m ∗ (Nlog2N +N) +N), m≪ n≪ N
Step 3 and 4 are computed with step 2, so the complexity
become:
O(n+m ∗Nlog2N), m≪ n≪ N
The complexity is not very high but can be very time
consuming due to the N value. In order to increase the speed
of an individual evaluation, the isotopic distributions of the
most common element are computed for a range of atomic
quantity. So the multiplication of the step 2 are no longer
needed. The speed is increased but the allocated memory
also.
An individual evaluation is a resource and time consuming
process. For example on a Pentium4 1.9Ghz, a protein of
500 amino acids needs in average one second and 300 Mo
of memory (constant value no linked to the protein size,
see above) to be evaluated in the default evaluation function
configuration. In this configuration, the theoretical spectrum
is represented by 65536 points (216). It can simulate peptides
with a mass contained in the interval [0, 4096] (in Da).
The accuracy of the spectrometer is considered to be 10−6.
The atomic isotopic distributions already calculated are only
based on the C atom quantity used (here 1000), the other
atom quantities are deduced from it (Xq means X atom
quantity):
Hq = 4 ∗ Cq Nq = Cq/2
Oq = Cq/4 Sq = Cq/8
These coefficients have been proposed by the proteomics
platform chemists. Thus the isotopic distributions for C from
C1 to Cq , for H from H1 to 4 ∗Cq , . . . are computed in the
evaluation function initialization. That is why there are 300
Mo of memory reserved, the most part is due to the different
isotopic distributions which are already computed.
This evaluation function has been validated by testing it
as a simple protein identification tool by PMF. We use the
UNIPROT database in FASTA format that can be download
at www.expasy.uniprot.org/database/download.shtml.
4) Operators: There are two types of operator: the
crossover and mutation operators. The crossover operator
allows from selected “parents” to generate “children”. The
mutation operators make small modifications on the individ-
uals to keep a genetic diversity in the population.
The chosen crossover is the well known 1-point crossover.
Two individuals are selected (the parents), a cut point is
randomly placed at the same position in the two individuals
and they exchange all the information positioned after this
cut point. Two new individuals (the children) are obtained,
they have information from the two initial individuals but
they are different.
Six mutation operators have been designed:
• The peptide insertion: a randomly generated peptide
is inserted in the peptide list that represents an
individuals. The size of the new peptides (in amino
acid) corresponds to the average size of all the peptides
that compounds the individuals. This mutation may
allow to reach new interesting peptides.
• The peptide deletion: A randomly chosen peptide
is deleted. This mutation may allow to increase the
individual quality by removing a peptide that penalizes
the individual fitness.
• The amino acid insertion: a random amino acid is
inserted in a peptide of the individual peptide list. This
new amino acid may not generate a new miss cleavage.
This mutation increases the peptide size.
• The amino acid deletion: a randomly chosen amino
acid is deleted of a peptide of an individuals. As the
amino acid insertion, this mutation modifies the peptide
size. With this mutation, the peptide size is decreased.
• The amino acid substitution: a randomly chosen amino
acid is replaced by another one not randomly chosen.
The new amino acid is taken according a probability
linked to the initial amino acid which is replaced. This
probability comes from a substitution matrix that gives
for each amino acid, the probability to be replaced
by another amino acid. The default matrix used is
the BLOSUM62 matrix [13] but others matrix can
be specified. This mutation may allow to modify the
chemical formula of the peptide without changing its
size (in amino acid).
• The post-translational modification: a post-translational
modification is added on a global peptide or on
a amino acid according to the modification. The
post-translational modifications are specific to proteins
and are very important in the protein activity. Some
proteins are only activated thanks to post-translational
modifications.
AAAAAAA BBBBBBB CCCCCCC
AAAAAAA DDDDDDDBBBBBBB CCCCCCC
CCCCCCCAAAAAAA
peptide insertion
peptide deletion
AAAAAAA CCCCCCCBBBBBB
CCCCCCCBBBBBBBAAAXAAA
amino acid substitution
amino acid deletion
amino acid insertion
AAAAAAA BBBBBBB CCCECCCC
post−translational modification
BBBBBBB CCCCCCCAAA*AAAA
Fig. 7
THE MUTATION OPERATOR: THE SIX TYPES OF MUTATION.
All these mutations, summarized in figure 7, can be
classified in two groups: the “tiny” mutations (amino acid in-
sertion/deletion/substitution and post-translational modifica-
tion) and “small” mutations (peptide insertion/deletion). The
“small” mutations have a bigger impact on the individuals
fitness than the “tiny” mutations.
As we have six types of mutation, it is difficult to set
the probability of each of them. To overcome this problem,
we implement an adaptive strategy for calculating the rate
of each mutation operator. Many authors have worked on
setting automatically probabilities of applying operator [14],
[15], [16]. In [17], authors proposed to compute the new rate
of mutation by calculating the progress of the jth application
of mutation operator Mi, for an individual ind mutated into
an individual mut as follows:
progressj(Mi) = Max(fit(ind), f it(mut))− fit(ind)
With this mechanism, we can evaluate the evolution of the
impact of each mutation operator during the GA execution.
Each part of the GA have been detailed. The next section
presents the first results of our approach.
III. RESULTS
In this section, the statistics concerning the GA behavior
are presented according to different configurations of the
parameters. Then a first biological validation of our approach
is proposed.
For all the experiments, we have used two types of data:
1) Experimental MS spectra: these spectra have been
given by the proteomics platform collaborator.
They have been produced by a MALDI-TOF mass
spectrometer. They correspond to real data from
current experiments.
2) Simulated MS spectra: these spectra are theoretical
spectra we have generated from protein sequences
in FASTA format. These type of data are useful to
make tests without noise and protein mix. They can
be considered as easy instances for our approach.
Furthermore, we can generate a lot of data because
only protein sequences are needed.
Table I summarizes the proteins used for our first tests.
TABLE I
MAIN DATA USED FOR OUR EXPERIMENTS. APO-AI:
APOLIPOPROTEIN-AI, CYT-C: CYTOCHROME-C. EXP: EXPERIMENTAL,
SIM: SIMULATED. THE PROTEIN LENGTH IS GIVEN IN AMINO ACIDS (AA)
AND THE PROTEIN WEIGHT IN DALTON (DA).
Name specie Type Size(aa) Weight(Da)
Apo-AI Human Exp ∅ ≃ 36000
Apo-AI Human Sim 317 36112.71
Cyt-C Bovine Exp ∅ ≃ 11500
Cyt-C Bovine Sim 104 11565.02
The experimental spectra have an estimated size de-
duced from their MS spectrum but we can not give
an estimated length for the experimental amino acid se-
quence as it is unknown. The simulated spectra have
been generated from the corresponding sequence in the
UNIPROT database in FASTA format that can be download
at www.expasy.uniprot.org/database/download.shtml. So the
simulated data sequence length and their weight are easily
computed. Take the same protein under the experimental and
the simulated format may allow to understand the difficulties
linked to experimental data (spectrometer calibration, noise,
. . . ).
A. GA behavior
In order to validate our approach, the GA behavior have
to be analyzed. According to the different version we have
developed for each part of our GA and all the different
parameters, a lot of configuration can be realized. Each
configuration test is time expensive due to the evaluation
function. So we have developed a parallel version of the
GA thanks to the ParadisEO platform [18]. Due to the
evaluation function cost, we have decided to parallelize the
individual evaluation according to a master/slave scheme.
The master initializes the population, the slaves evaluate it
and at each generation, the master computes the crossover,
the mutation and the population replacement steps whereas
the slaves compute the fitness of the new individuals. This
version has been used on the French grid called Grid5000
(www.grid5000.org). For each configuration test, we have
made 15 runs to make first statistics on few generations
(500). Concerning the crossover and mutation they have been
selected as follow:
• crossover rate: it has been set to 0.9 and
experimentations have not shown the necessity to
modify it.
• mutation rate: it has been set to 0.1 and with this rate,
the GA convergence was very slow. So we experiment
several rates of mutation in order to find the better
one. Finally, we set this rate with a 0.6 value. In
the following paragraphs, NAX GA will correspond
to the GA with a mutation rate of 0.X without the
adaptive mutation. AX will correspond to the GA with
a mutation rate of 0.X with the adaptive mutation.
Figure 8 shows the convergence improvement with
the Apolipoprotein-A1 example. Improve the mutation
rate (NA6 curve) allows to obtain the same quality of
solutions than the NA1 GA in only 110 generations.
At the end of the 500 generations, the individuals have
a fitness value 2 times better than they have with the
old mutation rate. We can also remark that the distance
between the NA1 and NA6 curves is globally the same
during the evolution. Thus, the gain is constant during
the 500 generations. With this new mutation rate value,
the GA behavior is better.
 0
 20
 40
 60
 80
 100
 120
 0  100  200  300  400  500
Fi
tn
es
s
Number of generations
low rate(0.1): best
low rate(0.1): means
high rate(0.6): means
high rate(0.6): best
high rate(0.6) and adaptive mutation: best
high rate(0.6) and adaptive muation: means
Fig. 8
EVOLUTION OF GA CONVERGENCE ACCORDING TO THE MUTATION
RATE VALUE AND THE ADAPTIVE MUTATION ACTIVATION STATE.
Furthermore, figure 8 shows also the convergence im-
provement when the adaptive mutation is activated. The final
individual quality of the NA1 GA is obtained in:
• only 110 generation for the NA6 GA.
• only 20 generation for the A6 GA.
We can remark that the distance between the A6 GA
and the NA6 GA increases during the 500 generations.
Concerning the final individual quality, comparing to the
NA1 GA, the fitness is:
• 2 times better for the NA6 GA.
• 4 times better for the A6 GA. Furthermore, the increas-
ing gain seems to continue in this case.
For each configuration of your GA, the same statistics
based on 10 runs will be exposed: the data used (experimental
spectrum or simulated spectrum), the optimal fitness with the
known protein corresponding to the MS spectrum (only in
the case of simulated spectra), the best individual fitness, the
fitness mean and the standard deviation. Table II presents
these statistics for the GA without adaptive mutation.
TABLE II
GA STATISTICS WITHOUT ADAPTIVE MUTATION. AAI: APO-AI HUMAN,
CC: CYT-C BOVIN. S/E: SIMULATED/EXPERIMENTAL SPECTRUM. σ:
STANDARD DEVIATION.
Data Max Best Mean Median σ
AAI S 78.47 52.8574 45.2751 45.8461 6.4019
AAI E ∅ 47.7902 36.3106 36.8451 7.3803
CC S 19.4578 15.5672 11.3776 11.324 2.56
CC E ∅ 44.5161 27.1763 25.7919 7.7616
We can remark that the protein size have an impact of
the individual fitness because the fitness obtained for Apo-AI
(experimental and simulated spectrum) is higher than the one
gained with Cyt-C (experimental and simulated spectrum).
Furthermore, the global statistics of our GA are better on
simulated data than experimental data. That is due to different
factor:
• the spectrometer calibration: as we compare spectra, we
estimate that the spectrometers are perfectly calibrated.
As the simulated spectra are “perfect” spectra, the GA
behavior is better.
• the spectrum noise: with experimental spectra, we have
all the information but also noise can be present.
• another proteins: when we gain a MS spectrum, there
are not peptides from only one protein. There are
always the possibility to have another protein peptides
(from the enzyme used for the digestion for example).
TABLE III
GA STATISTICS OF THE EXPERIMENTAL APOLIPOPROTREIN-AI (AAI E)
WITH ADAPTIVE MUTATION.
Data Max Best Mean Median σ
AAI S 78.47 72.4086 62.8111 68.0562 10.4471
AAI E ∅ 120.752 105.0315 106.8990 12.6105
CC S 19.4578 17.3078 14.0618 14.6003 2.6220
CC E ∅ 58.1147 45.1971 46.7804 8.7158
Table III shows the improvement of the experimental
Apolipoprotein-AI when the adaptive mutation is activated.
In the four cases, the best individual fitness is increased.
As the adaptive mutations are used, analyzing the operator
mutation rate variation allows to understand how the GA
evolves. The GA evolution is directly linked to the used
evaluation function. Figure 9 and 10 show how the operator
mutation rates move during the GA evolution for two con-
figuration of the evaluation function. The difference between
these two configurations concerns only the coefficient used
during the last step of an individual evaluation.
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EVOLUTION OF THE RATE MUTATION ACCORDING TO EACH MUTATION
(WITHOUT POST-TRANSLATIONAL MUTATION) WITH DEFAULT
EVALUATION FUNCTION CONFIGURATION.
In figure 9, the peptide insertion and the peptide dele-
tion are the mutation operator the most used during the
GA. However, in figure 10 the peptide insertion is rapidly
penalized whereas the peptide deletion is always the most
used mutation operator. Concerning the mutation rate for
the operators working on the amino acids (amino acid
substitution/deletion/ insertion), figure 9 shows that these
operators have different evolution curves but globally their
probability of being used decrease during the GA evolution.
On the contrary, in figure 10 these operators keep the same
behavior and their rate do not decrease nor increase.
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EVOLUTION OF THE RATE MUTATION ACCORDING TO EACH MUTATION
(WITHOUT POST-TRANSLATIONAL MUTATION) WITH ANOTHER
EVALUATION FUNCTION CONFIGURATION.
These results indicate that the configuration of the evalu-
ation function greatly influences the GA behavior.
After the study of the GA behavior, the first results of the
actual approach are proposed in the next part.
B. Biological validation
As we have already explained, experimental spectra and
simulated spectra have been used to test the GA behavior.
In the biological validation process, we used also these
two types of data to evaluate the robustness of our result
according to the spectrum quality. Our evaluation may allow
to find the right peptide chemical formula, so the best
individual may have a spectrum very similar to the data used.
For example, figure 11 shows the simulated spectrum of one
of the best individuals compared to the Apo-AI simulated
one. For the moment only the place of the peaks is analyzed,
not the peak intensity because the spectrum generation does
not compute the peak intensities. A high intensity for a
simulated spectrum only indicates that several peptides have
the same mass. In figure 11, we remark that the same peaks
are globally reached.
Fig. 11
APO-AI SIMULATED SPECTRUM VS BEST INDIVIDUAL SPECTRUM.
However, the peptide masses have also to be analyzed to be
sure of the similarity. If the below example is more precisely
analyzed (show in table IV), the individual peptides have the
right mass for 11 of them or very close mass for 20 of them.
In some case, the right sequence is also found. However,
having the right chemical formula (so the right mass) does
not seem that the same sequence has been found. Only further
work on MS/MS data can provide sequence information.
TABLE IV
MATCHING APO-AI PEPTIDES (AAI PEP) AND BEST INDIVIDUAL
PEPTIDES. δ IS THE MASS DIFFERENCE, δ= (|APO-AI PEPTIDE - BEST
INDIVIDUAL PEPTIDE|/APO-AI PEPTIDE). THERE ARE ALSO 11 EXACT
SEQUENCE MATCHES WHICH ARE NOT SHOWN HERE.
AAI pep δ AAI pep δ
278.153837 9.03 10−5 839.339148 3.93 10−5
347.229445 2.9 10−3 886.474654 2.00 10−5
381.213795 3.2 10−5 899.441563 2.05 10−5
561.263264 7.19 10−5 930.504892 1.07 10−3
603.335367 1.64 10−3 938.432714 9.94 10−4
616.378235 1.7 10−3 948.526690 1.18 10−11
678.393885 1.5 10−3 968.552905 6.25 10−5
804.373937 6.03 10−5 1114.585661 9.72 10−4
817.395676 2.27 10−5 1247.576887 1.11 10−5
830.437206 1.24 10−3 1647.801210 5.60 10−6
For the moment, our approach can not be compare for the
moment to another tool for two main reasons:
• our approach is not complete. The MS/MS evaluation
level is not already implemented and it is the next step
to reach the protein sequence.
• Only de novo peptide sequencing approaches can be
compared (with for example the Lutefisk tool). But
our approach is designed for making de novo protein
sequencing.
This approach may be used to give more information of
possible protein sequence modifications.
IV. CONCLUSIONS AND PERSPECTIVES
A first step for a fundamental approach to identify ex-
perimental protein sequence has been proposed. We have
designed a GA with a new evaluation function that avoid
a needed step in all the other methods using MS spectra:
the extraction of the mono isotopic list that needs human
intervention via a proprietary software linked to the used
spectrometer. The first tests have given interesting results.
The individual result of the GA evolution has a MS spectrum
closed to the experimental one. Therefore, the right chemical
formula are found. Furthermore, the size of each peptide (in
amino acids) is also correlated with the data. So the search
space is reduced.
However, the peptides of the result individuals generally
don’t have the right sequence and they are not in the right
order. To overcome these problems, (1) MS/MS spectra can
be used to find the right peptide sequence and (2) a MS
spectrum of the experimental protein gained with another
digestion enzym (for example pepsine) may allow to find
the right peptide order that gives the optimal fitness with the
new MS spectrum. This approch has been validated by the
proteomics platform collaborator and is under implementa-
tion.
Moreover, the study of the GA behavior has shown that the
current crossover used (the 1-point crossover) is not effective.
So two main possibilities to increase the GA behavior can
be proposed:
• Try other types of crossover or design a specific
crossover for our problem.
• Avoid the crossover utilization by using an another
optimization method, for example the taboo search.
Finally, this work may give a new way to analyze proteins
where the other methods do not give results.
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